Advanced glycation end products increase retinal vascular endothelial growth factor expression

Journal of Clinical Investigation

Volumn 101, Issue 6, 1998, Pages 1219-1224

  Lu, Ming ^a,b   Kuroki, Masatoshi ^a,b   Amano, Shiro ^a,b   Tolentino, Michael ^a,b   Keough, Karen ^a   Kim, Ivana ^a   Bucala, Richard ^c   Adamis, Anthony P ^a,b,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PICOWER INST FOR MEDICAL RESEARCH   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Advanced glycation end products; Diabetic retinopathy; Gene expression; Retina; Vascular endothelial growth factor

Indexed keywords

ANTIOXIDANT; GLYCOSYLATED PROTEIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CATTLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; MALE; NONHUMAN; PIGMENT CELL; PRIORITY JOURNAL; RABBIT; RAT; RETINA BIPOLAR GANGLION CELL; RETINA GANGLION CELL; VASCULAR SMOOTH MUSCLE;

EID: 0032520871     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1277     Document Type: Article

References (34)

1. Adamis, A.P., D.T. Shima, M. Tolentino, E.S. Gragoudas, N. Ferrara, J. Folkman, P.A. D'Amore, and J.W. Miller. 1996. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch. Ophthalmol. 114:66-71.
2. Aiello, L.P., E.A. Pierce, E.D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara, G. King, and L.E.H. Smith. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA. 92: 10457-10461.
3. Tolentino, M.J., J.W. Miller, E.S. Gragoudas, F.A. Jakobiec, E. Flynn, K. Chatzistefanou, N. Ferrara, and A.P. Adamis. 1996. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 103:1820-1828.
4. Adamis, A.P., J. Miller, M. Bernal, D.J. D'Amico, J. Folkman, T. Yeo. and K. Yeo. 1994. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118: 445-450.
5. Aiello, L.P., R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto, J.E. Park. et al. 1994. Vascular endothelial growth factor in ocular fluid of patients wth diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487.
6. Malecaze, F., S. Clamens, V. Simorre-Pinatel, P. Chollet, C. Favard, F. Bayard, and J. Plouet. 1994. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic rctinopathy. Arch. Ophthalmol. 112:1476-1482.
7. Amin, R.H., R.N. Frank, A. Kennedy. D. Eliott, J.E. Puklin. and G.W. Abrams. 1997. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 38:36-47.
8. Murata, T., K. Nakagawa, A. Khalil, T. Ishibashi, H. Inomata, and K. Sueishi. 1996. The relation between expression of vascular endothelial growth factor and breakdown of the blood retinal barrier in diabetic rat retinas. Lab. Invest. 74:819-825.
9. 1995. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. Arch. Ophthalmol. 113:36-51.
10. Wolffenbuttel, B.H., D. Giordano, H.W. Founds, and R. Bucala. 1996. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet. 347:513-515.
11. Stitt, A.W., Y.M. Li, T.A. Gardiner, R. Bucala, D.B. Archer, and H. Vlassara. 1997. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats. Am. J. Pathol. 150:523-531.
12. Makita, Z., H. Vlassara, A. Cerami, and R. Bucala. 1992. Immunochemical detection of advanced glycosylation end products in vivo. J. Biol. Chem. 267:5133-5138.
13. Yan, S.D., A.M. Schmidt, G.M. Anderson, J. Zhang, J. Brett, Y.S. Zou, D. Pinsky, and D. Stern. 1994. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269:9889-9897.
14. Armstrong, D., and F. al-Awadi. 1991. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Radic. Biol. Med. 11:433-436.
15. Kuroki, M., E.E. Voest. S. Amano, L.V. Beerepoot, S. Takashima, M. Tolentino, R.Y. Kim, R. Rohan, K. Colby, K. Yeo, and A.P. Adamis. 1996. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J. Clin. Invest. 98:495-504.
16. Vlassara, H., H. Fuh, Z. Makita, S. Krungkrai, A. Cerami, and R. Bucala. 1992. Exogenous advanced glycosylation end products induce complex vascular disfunction in normal animals: a model for diabetic and aging complications. Proc. Natl. Acad. Sci. USA. 89:12043-12047.
17. Wautier, J.-L., C. Zoukourian, O. Chappey, M.-P. Wautier, P.-J. Guillausseau, R. Cao, O. Hori, and A.-M. Schmidt. 1996. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97:238-243.
18. Hammes, H.P., S. Martin, K. Federlin, K. Geisen, and M. Brownlee. 1991. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA. 88:11555-11558.
19. Vlassara, H., M. Brownlee, and A. Cerami. 1985. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc. Natl. Acad. Sci. USA. 82:5588-5592.
20. FOX, C.H. 1993. In situ hybridization for detection of HIV RNA. In Current Protocols in Immunology, Vol. 2. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons, Inc., New York. 12.8.1-12.8.21.
21. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium triocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
22. Bullock, B.P., R.S. Heller, and J.F. Habener. 1996. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 137:2968-2978.
23. Shima, D.T., U. Deutsch, and P.A. D'Amore. 1995. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS (Fed. Eur. Biochem. Soc.) Lett. 370: 203-208.
24. Dodge, A.B., X. Lu, and P.A. D'Amore. 1993. Density-dependent endothelial cell production of an inhibitor of smooth muscle cell growth. Diabetes. 44:98-103.
25. Yamagishi, S., H. Yonekura, Y. Yamamoto, K. Katsuno, F. Sato, I. Mita, H. Ooka, N. Satozawa, T. Kawakami, M. Nomura, and H. Yamamoto. 1997. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272:8723-8730.
26. Tischer, E., R. Mitchell, T. Hartman, M. Silva, G. Gospodarowicz. J.C. Fiddes, and J.A. Abraham. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:11947-11954.
27. Shima, D.T., M. Kuroki, U. Deutsch, Y. Ng, A.P. Adamis, and P.A. D'Amore. 1996. The mouse gene tor vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of the transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 271:3877-3883.
28. Pe'er, J., R. Folberg, A. Itin, H. Gnessin, I. Hemo, and E. Keshet. 1996. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br. J. Ophthalmol. 80:241-245.
29. Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843-845.
30. Miller, J., A.P. Adamis, D.T. Shima, P.A. D'Amore, R.S. Moulton, M.S. O'Reilly, J. Folkman, H.F. Dvorak, L.F. Brown, B. Berse, et al. 1994. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145:574-584.
31. Pe'er, J., D. Shweiki, A. Itin, I. Hemo, H. Gnessin, and E. Keshet. 1995. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72: 638-645.
32. Augustin, A.J., W. Breipohl, T. Boker, J. Lutz, and M. Spitznas. 1993. Increased lipid peroxide levels and myeloperoxidase activity in the vitreous of patients suffering from proliferative diabetic retinopathy. Graefe's Arch. Clin. Exp. Ophthalmol. 231:647-650.
33. Hammes, H.P., A. Bartmann, L. Engel, and P. Wulfroth. 1997. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia. 40:629-634.
34. Frank, R.N., R. Amin, A. Kennedy, and T.C. Hohman. 1997. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch. Ophthalmol. 115: 1036-1047.